Regulus Therapeutics (RGLS)
(Real Time Quote from BATS)
$2.08 USD
+0.06 (2.97%)
Updated May 16, 2024 12:36 PM ET
2-Buy of 5 2
D Value D Growth D Momentum F VGM
Brokerage Reports
Regulus Therapeutics Inc. [RGLS]
Reports for Purchase
Showing records 241 - 260 ( 270 total )
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Announces RG-012 as Clinical Candidate in the Alport Syndrome Setting
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Announces RG-012 as Clinical Candidate in the Alport Syndrome Setting
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Regulus and Sanofi Renew Strategic Alliance and Regulus Receives Additional $10 Million Equity Investment; Raising Price Target to $19
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
February and 2014 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
February and 2014 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
January and 2014 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
January and 2014 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
December 2013 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of Dec. 2
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
December 2013 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Progress on Multiple Fronts Leading to Near-Term and 2014 Value Drivers; Reiterate OUTPERFORM and $17 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Progress on Multiple Fronts Leading to Near-Term and 2014 Value Drivers; Reiterate OUTPERFORM and $17 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Q3:13 financial results and update -- REITERATE OUTPERFORM and $17 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
We Believe a Compelling Preclinical Survival Benefit Warrants Anti-miR-21 Clinical Development; Reiterate OUTPERFORM and $17 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
We Believe Strong Preclinical RG-101 Data Has Potential for Once-Monthly Dosing; Clinical Trials to Start in 2014; Reiterate OUTPERFORM and $17 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
November and Remaining 2013 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
June And Remaining 2013 Catalysts For Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L